Myungin Pharm (317450) stock
KOSPI · Pharmaceuticals
As of the Nov 16 regular-session close (Korea)
Events and reference metrics · 1
- Market cap
- KRW 616.9 billion
- As of Nov 16, 2026
- P/E
- 7.58x
- Trailing twelve months
- P/B
- 0.76x
- Latest reported equity
- P/S
- 2.15x
- Trailing twelve months
- ROE
- 10.0%
- Trailing twelve months
- Dividend yield
- 4.73%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 616.9 billion
- As of Nov 16, 2026
- P/E
- 7.58x
- Trailing twelve months
- P/B
- 0.76x
- Latest reported equity
- P/S
- 2.15x
- Trailing twelve months
- ROE
- 10.0%
- Trailing twelve months
- Dividend yield
- 4.73%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
7.58x
P/B
0.76x
P/S
2.15x
Earnings and dividend metrics▾
Earnings
EPS
KRW 5,578
Earnings per share
BPS
KRW 55,915
Book value per share
ROE
10.0%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 5,578 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 55,915 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 10.0%.
Dividends
2 observed in the last year · Record dates: Aug, Dec
Yield
4.73%
Dividend per share
KRW 1,500
Payout ratio
26.9%
Consecutive years
2+ yrs
Yield uses dividends observed over the last year (by record date) · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about KRW 150,000 before tax.
- Payout ratio — 26.9% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 2 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 13, 2026 | KRW 76.1 billion | KRW 27.6 billion | KRW 24.3 billion | — |
| Q1 2026Consolidated · Filed May 14, 2026 | KRW 72.1 billion | KRW 25.1 billion | KRW 22.7 billion | — |
| Q4 2025Consolidated · Filed Mar 25, 2026 | KRW 72.1 billion | KRW 23.7 billion | KRW 23.3 billion | — |
| 9M 2025Consolidated · Filed Nov 12, 2025 | KRW 215.2 billion | KRW 68.8 billion | KRW 58.2 billion | +6.9% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 25, 2026 | KRW 287.3 billion | KRW 92.5 billion | KRW 81.4 billion | +6.6% |
| FY2024Consolidated · Filed Mar 25, 2026 | KRW 269.4 billion | KRW 92.8 billion | KRW 68.7 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Year-to-date rows are cumulative from the start of the fiscal year.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 0.41%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 0
- Previous 20-day average 11.71%
- Net short position
- 12,406 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 165,163 shares
- As of Nov 13, 2026 · 1.13% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 0.41% | KRW 0 |
| Nov 12, 2026 | 4.02% | KRW 10 million |
| Nov 11, 2026 | 5.06% | KRW 20 million |
| Nov 10, 2026 | 8.18% | KRW 50 million |
| Nov 9, 2026 | 20.16% | KRW 300 million |
| Nov 6, 2026 | 9.67% | KRW 100 million |
| Nov 5, 2026 | 15.41% | KRW 200 million |
| Nov 4, 2026 | 5.33% | KRW 40 million |
| Nov 3, 2026 | 16.36% | KRW 80 million |
| Nov 2, 2026 | 22.09% | KRW 70 million |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Preliminary Operating Results (Fair Disclosure)Nov 2, 2026 · Preliminary EarningsEnglish
- [Amended] Decision on Cash or In-kind Dividend(Korean)Aug 6, 2026 · Dividend
- Preliminary Operating Results (Fair Disclosure)(Korean)Jul 31, 2026 · Preliminary Earnings
- Decision on Cash or In-kind Dividend(Korean)Jul 28, 2026 · Dividend
- Record Date for Cash or In-kind Dividend(Korean)Jul 28, 2026 · Dividend
- Report on Changes in Shares Held by the Largest Shareholder and Related Parties(Korean)May 8, 2026 · Largest Shareholder Holding Change
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)May 8, 2026 · Insider Ownership Report
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)May 8, 2026 · Insider Ownership Report
Filings with a published English version open in English; the rest link to the Korean original.
Myungin Pharm (317450) stock information
KOSPI
Myungin Pharm (317450) is listed on KOSPI. Its market capitalization is about KRW 616.9 billion. On trailing-twelve-month earnings the P/E ratio is 7.58, and the P/B ratio is 0.76. Return on equity is 10%. These figures are computed in-house from official filings and are reference information only.
Myungin Pharm — frequently asked questions
- What is the P/E ratio of Myungin Pharm (317450)?
- On a trailing-twelve-month basis, 317450 trades at a P/E ratio of 7.58. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Myungin Pharm?
- 317450 has a market capitalization of about KRW 616.9 billion. The figure moves with the share price and is refreshed each trading day.
- Does Myungin Pharm pay a dividend?
- 317450 has a dividend yield of about 4.73%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.